期刊文献+

抗人CA19-9单克隆抗体的制备和鉴定及化学发光检测体系的建立 被引量:3

Preparation and characterization of the monoclonal antibodies against human CA19-9 and establishment of a sandwich CLIA system
下载PDF
导出
摘要 目的制备抗人糖抗原19-9(CA19-9)单克隆抗体(mAb),建立双抗体夹心检测CA19-9化学发光体系。方法 CA19-9免疫小鼠后,通过细胞融合技术,获得抗CA19-9的mAb。鉴定其抗体的纯度、效价、特异性和配对,建立双抗体夹心化学发光体系。在包被缓冲液、包被浓度及加样模式上优化化学发光体系,对该体系进行准确度、最低检测限、线性、重复性评估以及血清样本的检测。结果获得4株名称为#1-1、#2-1、#3-1和#4-1的mAb。抗体效价均大于10^-8,与CA125、CA15-3、CA72-4均无交叉反应。其中#3-1 mAb与#2-1-HRP建立的双抗体夹心体系经优化后,其检测范围为0~1 000 U/mL;最低检测限为2.0 U/mL;线性相关系数为0.9999。与罗氏试剂检测结果对比,Kappa系数大于0.75;相关系数大于0.9。结论成功制备了抗人CA19-9 mAb,建立了双抗体夹心检测CA19-9化学发光体系。 Objective To prepare the monoclonal antibodies(mAbs) against human carbohydrate antigen 19-9(CA19-9) and establish a double-antibody sandwich chemiluminescent immunoassay(CLIA) detection system for CA19-9 in the human serum. Methods BALB /c mice were immunized with human CA19-9 antigen. The mAbs were obtained by hybridoma technique. The purity,titer,specificity and pairing of the mAbs were characterized and the sandwich CLIA system was established. The system was evaluated in its accuracy,limit of detection,linearity and repetitiveness after optimization of coating buffer,coating concentration and pipetting mode,and the serum sample was tested with it. Results Four mAbs named #1-1,#2-1,#3-1 and # 4-1 were obtained against human CA19-9. The titers of the anti-CA19-9 mAbs were above10^-8. The mAbs had nearly no cross-reaction with CA125,CA15-3 and CA72-4. The double-antibody sandwich CLIA system was established by #3-1 mAb and #2-1 mAb-HRP. After optimization,its property was detection range of 0- 1 000 U /mL,limit detection of 2. 0 U /mL,linear correlation coefficient of 0. 9999. The results which were contrasted with Roche test showed that: Kappa 0. 75,r( correlation coefficient) 0. 9. Conclusion The mAbs against human CA9-9 have been prepared and a sandwich CLIA system for detecting CA19-9 in the human serum has been established successfully.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2014年第12期1282-1286,共5页 Chinese Journal of Cellular and Molecular Immunology
基金 黑龙江省应用技术研究与开发项目(GC13C122) 黑龙江省发展高新技术产业专项资金(FW11C201)
关键词 CA19-9 单克隆抗体 酶联免疫吸附分析 化学发光免疫分析 carbohydrate antigen 19-9 monoclonal antibody ELISA chemiluminescent immunoassay
  • 相关文献

参考文献20

  • 1Malati T. Tumour markers: An overview [ J ]. Indian J Clin Biochem, 2007, 22(2) : 17 -31.
  • 2l-lansson GC, Zopf D. Biosynthesis of the cancer-associated sialyl-Lea antigen[J]. J Biol Chem, 1985, 260(16): 9388 -9392.
  • 3Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies[ J]. Somatic Cell Genet, 1979, 5(6) : 957 -971.
  • 4Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9 [ J]. Clin Chem, 1983, 29(3) : 549 -552.
  • 5Yang GY, Malik NK, Chandrasekhar R, et al. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer [ J ]. J Gastrointest Oncol,2013, 4(4) : 361 -369.
  • 6Parikh DA, Durbin-Johnson B, Urayama S. Utility of serum CA19-9 levels in the diagnosis of pancreatic duetal adenoearcinoma in an endoscopic ultrasound referral population [ J ]. J Gastrointest Cancer, 2014, 45 ( 1 ) : 74 - 79.
  • 7Shukla VK, Gurubachan, Shanna D, et al. Diagaaostic value of serum CA242, CA19-9, CA15-3 and CA125 in patients with carcinoma of the gallbladder [ J ]. Trop Gastroenterol, 2006, 27 (4) : 160 - 165.
  • 8Agarwal AK, Kalayarasan R, Javed A, et al. Role of routine 16bl lymph node biopsy in the management of gallbladder cancer: an analysis[J]. HPB (Oxford), 2014, 16(3) : 229 -234.
  • 9Ychou M, Duffour J, Kramar A, et al. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer [ J ]. Dis Markers, 2000, 16 ( 3/4 ) : 105 - 110.
  • 10Leerapun A, Thaikruea L, Pisespongsa P, et al. Clinical features and prognostic factors for liver cancer from a referral center in northern Thailand [ J ]. J Med Assoc Thai, 2013, 96 ( 5 ) : 531 -537.

二级参考文献17

  • 1Hilkens J, Buijs F, Hilg.s J, et al. Monoclonal antibodies againsthuman milk-fat globule membranes detecting differentiation antigensof the mammary 成and and its tumors [ J]. Int J Cancer, 1984 , 34(2): 197 - 206.
  • 2Kufe D, Inghirami G, Abe M, et al. Differential reactivity of a novelmonoclonal antibody ( DF3 ) with human malignant versus benignbreast tumors[J]. Hybridoma, 1984, 3(3) ; 223 -232.
  • 3Dufiy MJ. Serum tumor markers in breast cancer: are they of clinicalvalue[J]. Clin Chem, 2006, 52(3) : 345 -351.
  • 4Duffy M J, Evoy D, McDermott EW. CA 15-3: uses and limitationas a biomarker for breast cancer[J]. Clin Chim Acta, 2010, 411 (23-24): 1869-1874.
  • 5Gonzdiez-Sistal A, Arias JI, Ruibal A. CA15-3 serum levels inpatients with ductal breast carcinoma : relationship with clinicopatho-logical parameters and tumor maiicersf J]. Int J Biol Markers, 2012,27(1): 47-52.
  • 6Paik S, Ahn HK, Park IX,et al. Implications of different CA15-3levels according to breast cancer subtype at initial diagnosis ofrecuiTent or metastatic breast cancer[ J]. Oncology, 2012, 82(3):180-187.
  • 7Yerushalmi R, Tyldesley S, Kennecke H, et al. Tumor markers inmetastatic breast cancer subtypes: frequency of elevation andcorrelation with outcome[ J]. Ann Oncol,2012 , 23 ( 2): 338 .345.
  • 8Lee JS, Park S, Park JM, et al. Elevated levels of preoperativeCA15-3 and CEA serum levels have independently poor prognosticsignificance in breast cancer[ J]. Ann Oncol, 2013, 24(5) : 1225-1231.
  • 9Sandri MT, Salvatici M’ Botteri E, et al. Prognostic roie of CA15.3in 7942 patients with operable breast cancer[ J] . Breast Cancer ResTreat, 2012,132(1) : 317-326.
  • 10Lumachi F, Basso SM, Bonamini M, et al. Relationship betweenpreoperative serum markers CA15-3 and CEA and relapse of thedisease in elderly ( > 65 years) women with breast cancer [ J].Anticancer Res, 2010,30(6) : 2331 -2334.

共引文献4

同被引文献38

  • 1Gareth Morris-Stiff,Mary Teli,Nicky Jardine,Malcolm CA Puntis.CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease[J].Hepatobiliary & Pancreatic Diseases International,2009,8(6):620-626. 被引量:33
  • 2Oya Uygur-Bayramicli,Resat Dabak,Ekrem Orbay,Can Dolapclo■lu,Mehmet Sargin,Gamze Kilico■lu,Yüksel Güleryüzlü,Alpaslan Mayada■li.Type 2 diabetes mellitus and CA 19-9 levels[J].World Journal of Gastroenterology,2007,13(40):5357-5359. 被引量:64
  • 3Ma J, Dushoff J, Earn DJ. Age-specific mortality risk from pandemic influenza[J]. J Theor Biol. 2011,11(288) :29-34.
  • 4Pales P.Influenza: old and new threats [J]. Nature Medicine Supplement, 2004,10(12) :$82-$87.
  • 5Htiper D, Kalthoff D, Hoffmann B,et al. Highly Pathogenic Avian Influenza Subtype H5N1 escaping neutralization: more than HA variation[J]. J Virot,2012,86(3):1394-1404.
  • 6Webster RG. Wet markets-a continuing source of severe acute respiratory syndrome and influenza[J]. Lancet,2004,363 (9404) : 234-236.
  • 7Michelle Q,Ann C,Maura N, et al. Comparison of sensitivities of virus isolation, antigen detection, and nucleic acid amplifi- cation for detection of equine influenza virus [J]. J Clin Micro- biol, 2004, 42(2): 759-763.
  • 8Weinberg A, Walker M L. Evaluation of three immunoassay kits for rapid detection of influenza virus A and B [J]. Clin Diagn Lab Immunol,2005,12(3) :367-370.
  • 9徐飞海,王锐,白佳伟,齐先佳,陈毅歆,葛胜祥,张军,夏宁邵.一种A型流感病毒NP抗原快速检测试剂的建立[J].中国人兽共患病学报,2008,24(1):22-25. 被引量:8
  • 10吴晓蓉,张玉强,胡惠民,邹祝英,刘森炎,马熠熠.慢性肾衰竭患者血清CA125与CA199的临床意义[J].中国中西医结合肾病杂志,2008,9(5):438-439. 被引量:11

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部